Clinical

Latest News


Latest Videos


More News

4 KOLs are featured in this series

Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.

1 expert in this video

Paul Feuerstadt, MD, FACG, AGAF, discusses how testing for Clostridioides difficile is recommended for hospitalized patients or outpatients with new-onset, unexplained diarrhea who have risk factors such as recent antibiotic use, hospitalization, or older age, and how empiric treatment should be initiated while awaiting test results if there is high clinical suspension.

1 expert in this video

The panelist discusses how antibiotics are paradoxically both the primary treatment for Clostridioides difficile infections and a major risk factor for recurrence since they disrupt the protective gut microbiome, which led to the development of alternative therapies like fecal microbiota transplantation to restore microbial balance and prevent reinfection.

Big Data | Image Credit: © Friends Stock-stock.adobe.com

This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.